Follicum’s clinical phase I/IIa trial, conducted with healthy humans, shows that the hair growth is stimulated with 8 % in 76 % of the individuals compared to before treatment – an increase wich is statistically verified (p=0,0038, non-multiply adjusted). The data from our trial also shows a significant higher effect when comparing three to two times treatment per week. This indicates that the frequency of treatment is important to optimise the effect of the drug. Placebo showed a decrease of 2 % in growth (p=0,4613).
Further steps in the clinical development of FOL-005 is to go through with phase II and phase III trials. The first of these, a phase IIa on human scalps, will commence early 2018. We are also running a project that will decide which topical formulation of our drug we will use in the phase IIb clinical trial . Our research follows several different tracks in order to understand if an ointment, a cream or a formulation with dry powder will be the optimal choice. Prototypes have been developed and are currently tested. The chosen formulation will then be tested in clinical phase IIb and III trials before the launch of our drug.